ProHealth me-cfs Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

ADHD (Attention Deficit Hyperactivity Disorder) May Be Common in Fibromyalgia

Be Your Own Researcher: Treat Chronic Pain as a Daily Experiment

NEID Disease? Study Suggests Neuro, Endocrine and Immune Systems Work Together to Produce ME/CFS

The Depression Puzzle: Are Anti-inflammatories Better Than Antidepressants? An ME/CFS and FM Perspec...

Is Acceptance Just Resignation?


Improvement of severe myalgic encephalomyelitis/chronic fatigue syndrome symptoms following surgical...

The Cortene Way: New Drug to Be Trialed in Chronic Fatigue Syndrome (ME/CFS) Soon – Pt. I

Eukaryotes in the gut microbiota in myalgic encephalomyelitis/chronic fatigue syndrome

The Opioid "Crisis" - Do we need to go "Back to the Future" to Respond Effectively?

Print Page
Email Article

Could we finally have a definitive biomarker for ME/CFS?

  [ 35 votes ]   [ 1 Comment ]
By ME Research UK • • June 22, 2017

Could we finally have a definitive biomarker for ME/CFS?
Reprinted with the kind permission of ME Research UK.

It’s a recurring theme, but the diagnosis of ME/CFS is severely hampered by the lack of a test that can distinguish people with the illness from those without. This is a challenge in many diseases, but particularly in ME/CFS which affects so many different systems of the body.

ME/CFS is currently identified by the presence of specific signs and symptoms, but there are several different criteria in use, and much debate over which are the most precise or appropriate. The quest for a biomarker is therefore a top priority since an accurate diagnosis is essential for patients to receive the medical care they need.

Generally speaking, biomarkers are measurable substances or processes in the body that can indicate the risk, presence or severity of a disease, or how well it will respond to a specific treatment.

For example, a high white blood cell count may indicate the presence of an infection, while raised levels of prostate-specific antigen in the blood are associated with an increased risk of prostate cancer.

Researchers have looked at a number of different measures as potential biomarkers for ME/CFS, including brain imaging findings, ECG abnormalities, and immunosignatures based on antibodies in the blood.

In fact, ME Research UK has recently funded work to look for an immunosignature that can predict patients’ responses to rituximab therapy.

New research from a team in Australia, led by Prof. Brett Lidbury at the Australian National University in Canberra, has added another potential biomarker to this list.

Prof. Lidbury has a longstanding interest in the search for biomarkers for ME/CFS, and ME Research UK recently awarded his group funding to analyse genetic data which might provide clues about the mechanisms of the disease.

But in this recent study, published in the Journal of Translational Medicine, the team focused on a different potential biomarker: activin.

The two types of activin (A and B) are produced in several organs in the body, and have a number of different roles, including regulation of the menstrual cycle, and involvement in metabolism and wound repair.

Prof. Lidbury is interested in two of its functions which have particular relevance to ME/CFS, namely the control of inflammation and muscle mass. Inflammation is important because the immune system is thought to be involved in the illness, while muscle mass will have an obvious influence on muscle weakness and pain.

The researchers took blood samples from 45 patients with ME/CFS (as defined by the Canadian Diagnostic Criteria) and from 17 healthy controls.

Concentrations of both activin A and activin B were measured (as they have some different functions), as well as follistatin (a binding protein that regulates levels of activin).

Levels of activin B in the blood were markedly higher in the ME/CFS patients than in the healthy individuals (and also higher than in a previously studied normal group), whereas activin A and follistatin levels were no different.

This exciting finding suggests that the combination of elevated activin B and normal activin A may represent a useful biomarker for the presence of ME/CFS, although this would need to be validated in larger groups of patients.

Another intriguing prospect is whether follistatin might have some value as a treatment for ME/CFS since it can inhibit the actions of activin B. In fact, follistatin could have a two-pronged attack because it also blocks myostatin, a protein that inhibits muscle cell growth.

Prof. Lidbury’s study has certainly borne fruit, giving us a potential diagnostic biomarker for ME/CFS, as well as some hope for a new treatment. It’s early days on both fronts, however, so we will be keeping a close eye on further developments from this group.

ME Research UK is a Scottish Charitable Incorporated Organisation (charity number SC036942) funding biomedical research into ME/CFS and related illnesses. Our principal aim is to commission and fund high-quality scientific (biomedical) investigation into the causes, consequences and treatment of ME/CFS, but we also have a mission to "Energise ME Research"

Post a Comment

Featured Products From the ProHealth Store
Hydroxocobalamin Extreme™ Energy NADH™ 12.5mg MitoQ®

Article Comments Post a Comment

We desperately need a definitive biomarker!
Posted by: curecfs
Jul 12, 2017
I hope I live to see the day this 42 and already suffering over 2 decades with this, I don't expect to be cured, but it would be nice to at least be finally validated and have proof for my doctors and friends, and to know what really is going wrong with my body too!
Reply Reply
Optimized Curcumin Longvida with Omega-3

Featured Products

Hydroxocobalamin Extreme™ Hydroxocobalamin Extreme™
The B-12 Your Brain Needs for Detox & Sharpness
MitoQ® MitoQ®
Powerful Antioxidant Support to Mitochondria
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
B-12 Extreme™ B-12 Extreme™
The Most Potent Vitamin B-12 on Earth
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%

Natural Remedies

Mitochondria-Booster NIAGEN® Shows Promise in First Human Clinical Trial Mitochondria-Booster NIAGEN® Shows Promise in First Human Clinical Trial
The Super Antioxidant for Brain, Joint and Heart Health The Super Antioxidant for Brain, Joint and Heart Health
How One Tiny Molecule Turned into One Huge Health Breakthrough How One Tiny Molecule Turned into One Huge Health Breakthrough
Natural Bladder Control, Go Less and Live More Natural Bladder Control, Go Less and Live More
Pioneer Scientists Uncover a Revolutionary Neuroprotective Supplement for Nerve Health Pioneer Scientists Uncover a Revolutionary Neuroprotective Supplement for Nerve Health

ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
Credit Card Processing
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2018 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map